Send PM
Followers 3
Posts 1139
Boards Moderated 0
Alias Born 06/06/2017

Re: None

Tuesday, 09/06/2022 12:56:41 PM

Tuesday, September 06, 2022 12:56:41 PM

Post# of 33960
Let's Toke Business-Ted Ohashi
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_03c92dcde04a4361ae4538084bed2dc9.pdf
Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) made a couple of announcements recently that many investors may have missed on overlooked. I will tell you what they were and why I think they are very important.
• LEXX announced that Catherine Turkel, PharmD, PhD has joined its board of directors.
The release reports that Dr. Turkel has more than 20 years' experience as an executive in start-up and mid-size pharma/biotech companies. She was Founder and CEO of Nezee Therapeutics and served as President and R&D head at Novus Therapeutics (renamed Eledon Pharmaceuticals - Nasdaq: ELDN). She currently acts as an independent Board Director at Object Pharma (private) and Prostate Cancer Research (non-profit; member of the Translational Scientific Advisory Committee) and is a Dean Advisor at Chapman University School of Pharmacy. Dr. Turkel has formulated Food and Drug Administration registration & commercial strategic plans and has led global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 related to Neurosciences, Pain, Cardiovascular, Psychiatry, Rare Diseases, Ophthalmology, Aesthetics, Urology and Otology therapeutic areas. Dr. Turkel designed and led Allergan's (now AbbVie - NYSE: ABBV) pioneering BOTOX® Chronic Migraine registration program, generating revenue of more than a billion dollars.
• LEXX has received its 27th worldwide patent granted in Mexico. The patent is from their third patent family, "Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents" that includes patents have already been issued in Australia, India and Japan. Certain claims allowed in this Mexican patent to use DehydraTECH-processed nonpsychoactive cannabinoids to treat cardiac and cardiometabolic disorders are of particular value to the Company. It also includes the treatment of Alzheimer's, Parkinson's, schizophrenia, and Human Immunodeficiency Virus (HIV) dementia; obesity; metabolic disorders
such as insulin related deficiencies and lipid profiles, hepatic diseases, diabetes, and appetite disorders; cancer chemotherapy; benign prostatic hypertrophy; irritable bowel syndrome; biliary diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine, or cocaine addiction.
Conclusion: In broad brush strokes, here is what I expect from Lexaria Bioscience (NASDAQ: LEXX)
(NASDAQ: LEXXW). In the next six to nine months, I expect LEXX to receive approval from the FDA to initiate testing DehydraTECH-CBD as a treatment for hypertension. In the six to twelve months after that, I expect LEXX will conclude an agreement with a larger pharmaceutical company to complete the FDA approval process. If these objectives are met, I have shown in previous reports that LEXX’s market cap could be a ten-bagger or better in the next 12 – 24 months.
However, this is not the end of the story. If this were to happen, it would be a rare and tremendous accomplishment for LEXX but there would still be many opportunities ahead, some of which were covered in the Mexican patent above. Therefore, it is important to keep building the intellectual property values in the form of patents and to attract new and highly qualified people to join in the effort.
If LEXX gets to this point with hypertension in the next six to twelve months, CEO Chris Bunka and President John Docherty might step back and assume less active roles. But as investors, we may continue to benefit from today’s investment for decades to come. If you look at the charts above for the shares and warrants, you will see a pattern of accumulation since
mid-June. This is in stark contrast to what happened in the year or two previous when news would spark a sharp rally followed shortly by an equal or greater quick correction. This suggests to me that with what LEXX has underway at present, we may never see these prices again. This may be your last chance to accumulate LEXX at these extremely attractive price levels.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Recent LEXX News

Branded Legacy, Inc. Signs Joint Venture To Add Additional $300,000 a Year In Revenue BLEG Nov 23, 2022 11:10 AM

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial CMND Nov 23, 2022 9:50 AM

Branded Legacy, Inc. Gets Approval From State to Reduce Authorized Common Shares by 300 Million BLEG Nov 22, 2022 1:15 PM

Defiance Resumes Drilling In Zacatecas DNCVF Nov 22, 2022 11:53 AM

InnerScope Hearing Technologies (OTC: INND) Announces its HearingAssist Brand of OTC Hearing Aids on RiteAid.com INND Nov 22, 2022 11:52 AM

ECRID Offers Federal Housing Finance Agency (FHFA) Credit & Lending Platform to Immediately Assist Low-Credit and No-Credit Home Buyers, and Others ECDD Nov 22, 2022 11:51 AM

BioLife Sciences Inc. (OTC:PK BLFE) is Pleased to Announce Its Q1 2023 Slated Release of Its Copper-Infused Fabric Pot Prototype BLFE Nov 22, 2022 11:50 AM

Fission 3.0 Hits Off-Scale Radioactivity in New Discovery on PLN A1 Conductor FUU Nov 21, 2022 11:05 AM

Perpetual Industries Reports Strong Third-Quarter PRPI Nov 21, 2022 8:00 AM

Nextech AR Solutions Corp. Reports Record Q3 Sequential Growth As 3D Modeling Revenue Surges +192% and Gross Profit Margin Improves To +60% NEXCF Nov 17, 2022 7:03 PM

AgriFORCE Receives Notice of Allowance Related to its FORCEGH+ Facility from the United States Patent and Trademark Office AGRIW Nov 17, 2022 9:06 AM

Organicell Starts Enrolling Long COVID Trial OCEL Nov 17, 2022 8:38 AM

Mullen Announces Funding to Close on ELMS Assets MULN Nov 17, 2022 8:30 AM

Maison Luxe Reports Revenues of Approximately $3.7 Million for the Quarter Ended September 30, 2022 as Compared to Approximately $2.7 Million for the Quarter Ended September 30, 2021, an increase of over 35% MASN Nov 17, 2022 8:19 AM

SKYX Wins Consumer Electronics Show (CES) 2023 Innovation Award for Smart Home Category for Smart Sky Ceiling Plug SKYX Nov 17, 2022 8:07 AM